TrialA Study of LY3471851 in Adults With Systemic Lupus Erythematosus (SLE)
Trial details
- Registry ID
- NCT04433585
- Phase
- Phase 2
NKTR
Nektar Therapeutics
Company identity checked against sources
Browse linked trials and recorded changes, or follow this company for updates.
5Trials in this database
3Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far
Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.
Completion dates · Pro
Which trial dates moved later?
Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features
Included trials
Check company identity source| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Study of LY3471851 in Adults With Systemic Lupus Erythematosus (SLE)NCT04433585 | NKTR | Phase 2 | Completed | 2023-01-10Actual |
| A Study of LY3471851 in Adult Participants With Moderately to Severely Active Ulcerative Colitis (UC)NCT04677179 | NKTR | Phase 2 | Terminated | 2022-08-09Actual |
| NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large B-cell LymphomaNCT05664217 | NKTR | Phase 2, Phase 3 | Terminated | 2024-05-22Actual |
| A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic DermatitisNCT06136741 | NKTR | Phase 2 | Active not recruiting | 2025-05-06Actual |
| A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Severe to Very Severe Alopecia Areata in Adult Patients (Rezolve AA)NCT06340360 | NKTR | Phase 2 | Completed | 2025-11-26Actual |
A Study of LY3471851 in Adult Participants With Moderately to Severely Active Ulcerative Colitis (UC)
Trial details
- Registry ID
- NCT04677179
- Phase
- Phase 2
NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large B-cell Lymphoma
Trial details
- Registry ID
- NCT05664217
- Phase
- Phase 2, Phase 3
A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis
Trial details
- Registry ID
- NCT06136741
- Phase
- Phase 2
A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Severe to Very Severe Alopecia Areata in Adult Patients (Rezolve AA)
Trial details
- Registry ID
- NCT06340360
- Phase
- Phase 2
Latest recorded trial changes
A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Severe to Very Severe Alopecia Areata in Adult Patients (Rezolve AA)
NCT06340360 · Nektar Therapeutics
Recruitment status changed
− Before
Active not recruiting
+ After
Completed
A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Severe to Very Severe Alopecia Areata in Adult Patients (Rezolve AA)
NCT06340360 · Nektar Therapeutics
Completion date type changed
− Before
Estimated
+ After
Actual
Primary completion date changed
− Before
Nov 2025
+ After
26 Nov 2025